Alnylam Pharmaceuticals's Earnings Outlook
Portfolio Pulse from Benzinga Insights
Alnylam Pharmaceuticals (NASDAQ:ALNY) is expected to report a Q4 EPS of $-1.33 on February 15, 2024. Analysts and investors will be looking for positive guidance beyond the earnings beat or miss. The company's past performance shows a mix of earnings beats and misses with corresponding stock price changes. Shares are currently down 25.86% over the last 52 weeks, trading at $162.0 as of February 13.
February 14, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals is anticipated to report a Q4 EPS of $-1.33, with a focus on future guidance. Shares have declined 25.86% over the past year.
The expected EPS and the emphasis on future guidance suggest a neutral to potentially positive outlook, depending on the actual earnings report and guidance provided. The past performance indicates that earnings beats or misses can significantly impact the stock price. However, the current year-to-date decline suggests a cautious market sentiment towards ALNY.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100